Thursday, September 19, 2024

clinical trials

Finerenone Meets Primary Endpoint in Phase III Study

Finerenone Meets Primary Endpoint in a Phase III cardiovascular outcomes study, Bayer recently announced the positive results from its Phase III FINEARTS-HF study, which evaluated the efficacy and safety of finerenone in patients with heart failure with mildly reduced...

Bayer’s New Drug Application Has Submitted to FDA for Elinzanetant

Bayer's new drug application has submitted to the US FDA for elinzanetant. They disclosed this information in a statement on their website on August 1, 2024. They have submitted the new application targeting the treatment of moderate to severe...

Latest News

Walmart: History, Growth, Impact, and Future in Global Retail

Introduction Walmart stands as one of the largest and most influential retail corporations in the world. Founded in 1962 by...